Trial Profile
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Dec 2021
Price :
$35
*
At a glance
- Drugs PF 5212366 (Primary)
- Indications Meningococcal group B infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Pfizer
- 29 Jun 2021 Results published in the Vaccine
- 12 Feb 2019 Interim Results(n=736) assessing Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp published in the Vaccine
- 05 Feb 2018 Status changed from recruiting to completed.